Search results
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach...
Morningstar· 4 days agoPALM BEACH, Fla., June 20, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Pancreatic cancer is among the most frequently diagnosed and the seventh ...
In vitro photothermal therapy of pancreatic cancer mediated by immunoglobulin G-functionalized...
Nature· 2 days agoPancreatic cancer is one of the most aggressive forms of cancer, and treatment options are limited ...
Biotech Advances Propel Oncology Market to $564.5B Amid Youth Cancer Spike
Morningstar· 4 days agoUSA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number of cancer cases ...
Anti-inflammatory drug celecoxib could reduce risk | Newswise
Newswise· 6 days agoBoston – An analysis of data from a randomized clinical trial for patients with stage 3 colon cancer...
Zentalis Pharmaceuticals’ (ZNTL) “Equal Weight” Rating Reaffirmed at Morgan Stanley
ETF DAILY NEWS· 5 days agoMorgan Stanley restated their equal weight rating on shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL – Free Report) in a research note published on Tuesday morning, MarketBeat reports. Other ...
Truqap Combo Earns EU Approval for Advanced Breast Cancer
Medscape· 3 days agoThe approval is based on positive results from the phase 3 CAPItello-291 trial.
Roswell Park Insights on Role of Exportin 1 Protei | Newswise
Newswise· 4 days agoResearch by Hemn Mohammadpour, DVM, PhD, and colleagues at Roswell Park Comprehensive Cancer Center offers new insights into tumor biology and may lay the
Drug reprograms immune responses to target glioblastoma
Medical Xpress· 6 days agoInvestigators from Northwestern University Feinberg School of Medicine and The University of Texas...
GenFleet Receives IND Approval from China's NMPA for GFH375, an Oral KRAS G12D (ON/OFF) Inhibitor,...
Tehachapi News· 5 days agoG12D mutation is the most prevalent KRAS mutation detected in human cancers, and no G12D-targeted therapies have been approved yet.
Autonomix appoints new CEO, shifts former leader to board By Investing.com
Investing.com· 7 days agoAutonomix Medical, Inc. (NASDAQ: AMIX), a company specializing in medical devices for neurological...